Track topics on Twitter Track topics that are important to you
As patients grapple with increasing prices for insulin, many stakeholders have been the subjects of intense scrutiny as the diabetes community searches for solutions.Debate has swirled around who is to blame for insulin prices that have greatly outpaced inflation over the last decade. In November, the American Diabetes Association called on Congress to hold hearings with all entities in the insulin supply chain, including manufacturers, wholesalers, pharmacy benefit managers (PBMs), insurers and pharmacies, and asked those same groups to substantially increase transparency in pricing associated with the delivery of insulin to the patient.
Original Article: At Issue: The complexity of insulin’s high costNEXT ARTICLE
Endocrine disorders are grouped into two categories: hormone imbalance - when a gland produces too much or too little of an endocrine hormone development of lesions (such as nodules or tumors) in the endocrine system, which may or may not affect...